StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$2.83−0.29 (-9.29%)

Close on Nov 16, 2026Market cap $280.59MP/E –Yield –

X4 Pharmaceuticals total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

X4 Pharmaceuticals's total debt was $54.57M at Dec 31, 2023. For fiscal 2023 it was $54.57M, up 62.3% from the year before. The highest annual figure on record is $54.57M in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2023Dec 31, 2023$54.57M+62.3%
FY2022Dec 31, 2022$33.62M-0.9%
FY2021Dec 31, 2021$33.93M+2.3%
FY2020Dec 31, 2020$33.18M+65.9%
FY2019Dec 31, 2019$20.00M+100.0%
FY2018Dec 31, 2018$10.00M–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2023Dec 31, 2023$54.57M+273.2%
Q2 FY2023Jun 30, 2023$764.00K-91.1%
Q1 FY2023Mar 31, 2023$554.00K-83.8%
Q4 FY2022Dec 31, 2022$33.62M-0.9%
Q3 FY2022Sep 30, 2022$14.62M+2009.8%
Q2 FY2022Jun 30, 2022$8.61M-74.1%
Q1 FY2022Mar 31, 2022$3.42M-82.9%
Q4 FY2021Dec 31, 2021$33.93M+69.7%
Q3 FY2021Sep 30, 2021$693.00K-97.4%
Q4 FY2020Dec 31, 2020$33.18M+69.7%
Q4 FY2019Dec 31, 2019$20.00M+100.0%
Q3 FY2019Sep 30, 2019$20.00M–
Q2 FY2019Jun 30, 2019$26.35M–
Q1 FY2019Mar 31, 2019$19.55M–
Q4 FY2018Dec 31, 2018$10.00M–

More X4 Pharmaceuticals figures

See a number that looks wrong?